As shown in Table S2, adding u[TIMP-2]*[IGFBP7] to the clinical risk factor model resulted in the greatest improvement in risk reclassification both for the primary and the secondary outcomes, with a category-free net reclassification index (NRI) of 0.63 and 0.59 for AKI progression and AKI progression with death. This evidence concerns the gene TIMP2 and acute kidney injury.